Want to see ARMP full AI Analyst Report?
ARMP Stock Chart & Stats
$4.66
$0.06(1.29%)
At close: 4:00 PM EDT
$4.66
$0.06(1.29%)
Day’s Range― - ―
52-Week Range$2.36 - $16.34
Previous CloseN/A
Volume56.99K
Average Volume (3M)213.69K
Market Cap
$175.48M
Enterprise Value$742.99
Total Cash (Recent Filing)$4.75M
Total Debt (Recent Filing)$373.67M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 18, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.77
Shares Outstanding36,710,810
10 Day Avg. Volume216,533
30 Day Avg. Volume213,691
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.50Price Target Upside275.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.9
Revenue Forecast (FY)$1.80M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress & Phase 3 ReadinessFDA Fast Track and QIDP designations plus a submitted Phase 3 protocol and End‑of‑Phase‑2 responses materially reduce regulatory uncertainty. These durable developments enable more frequent agency interactions and potential accelerated review, improving the structural pathway to approval if pivotal results are positive.
Non-dilutive DoD FundingSubstantial non‑dilutive Department of Defense support (totaling $28.7M) funds Phase‑3 readiness activities and signals government validation. This durable external funding reduces near‑term capital pressure, supports program continuity, and de‑risks specific development milestones versus relying solely on equity markets.
Manufacturing Progress And Strengthened Finance LeadershipCompletion of cGMP engineering runs and planned production of Phase‑3 material show growing in‑house manufacturing capability, a critical durable asset for biologics. Promoting an experienced internal finance leader to CFO strengthens capital planning and execution capacity during costly late‑stage development.
Bears Say
Stressed Balance Sheet / Negative EquityNegative stockholders' equity is a structural red flag that limits financial flexibility and distorts leverage metrics. Persistent negative equity elevates refinancing and dilution risk, making it harder to secure favorable financing as the company undertakes expensive pivotal trials and commercialization preparations.
Persistent Cash Burn And Weak Cash GenerationConsistently negative operating and free cash flow, with worsening free cash flow in the trailing twelve months, indicate the business cannot self‑fund development. Ongoing cash burn structurally necessitates external capital, increasing execution risk and the probability of dilutive financing during multi‑year clinical programs.
Tight Liquidity And Reliance On External FinancingLow reported cash, a large secured term loan and a sharply widened quarterly net loss highlight constrained liquidity. Dependence on Innoviva and other financings increases refinancing and covenant risk, potentially forcing dilutive raises or program delays if anticipated non‑dilutive support or capital markets access falters.
Armata Pharmaceuticals News
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $2.36 and its highest was $16.34 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $175.48M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Aug 18, 2026 which is in 16 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on May 13, 2026. The company reported -$3.16 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$2.78.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.45.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,710,810 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$3.16 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went down -7.029%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (275.54% Upside)
$17.50 (275.54% Upside)
Blogger Sentiment
Bearish
ARMP Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 12.4%
Last 30 Days ▲ 12.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
87.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.00%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
ARMP Stock 12 Month Forecast
Average Price Target
$17.50
▲(275.54% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
1.36% Mutual Funds
0.25% Other Institutional Investors
95.16% Public Companies and
Individual Investors